Skip to main navigation Social icons About Us Health innovation that matters Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncology and NASH. btn About Learn More Press Releases and Company Announcements Recent News NOV 03, 2021 Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Learn More OCT 26, 2021 Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1 Learn More btn News View All Pipeline Product Pipeline Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently have a Phase 1 clinical trial underway in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH, a severe liver condition which affects a growing number of people around the world. btn Pipeline Learn About Hepatology Learn About Oncology Learn About HIV pipeline Phases Preclinical Phase 1 Phase 2 Phase 3 Approved Marketed NASH Tesamorelin F8 Oncology TH 1902 TH 1904 Corporate Presentation Making a difference through innovation Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs. Download PDF Commercialized Medicine Our Commercialized Products Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is approved in the United States while EGRIFTA® is available only in Canada. btn Medicine Learn About Trogarzo® Learn About EGRIFTA SV® Learn About EGRIFTA® HIV Portfolio HIV Portfolio Preclinical Phase 1 Phase 2 Phase 3 Approved Marketed HIV Trogarzo ® Trogarzo ® EU Trogarzo ® IV Push EGRIFTA® EGRIFTA SV® Trogarzo ® Intramuscular Tesamorelin F8 in HIV-associated lipodystrophy Headquarters Theratechnologies inc. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 European Headquarters Theratechnologies Europe Limited 2 Hume Street, 4th floor Dublin 2 Ireland D02 DV24 Phone: +353 1 215 0650 europe@theratech.com Investor Relations Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1 438-315-6608 ir@theratech.com US Headquarters Theratechnologies U.S., Inc. 101 Hudson Street 21st Floor Jersey City, New Jersey 07302 Main Nav HOME ABOUT MEDICINES & PIPELINE INVESTORS CORPORATE RESPONSIBILITY CAREERS CONTACT US ©2021 - Theratechnologies Inc. Legal Nav Terms of Use Privacy